Robert S Jansen

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2208884/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Activity-based annotation: the emergence of systems biochemistry. Trends in Biochemical Sciences, 2022, 47, 785-794.	7.5	8
2	CinA mediates multidrug tolerance in Mycobacterium tuberculosis. Nature Communications, 2022, 13, 2203.	12.8	22
3	An exercise-inducible metabolite that suppresses feeding and obesity. Nature, 2022, 606, 785-790.	27.8	96
4	Whole Cell Active Inhibitors of Mycobacterial Lipoamide Dehydrogenase Afford Selectivity over the Human Enzyme through Tight Binding Interactions. ACS Infectious Diseases, 2021, 7, 435-444.	3.8	1
5	A novel methoxydotrophic metabolism discovered in the hyperthermophilic archaeon <i>Archaeoglobus fulgidus</i> . Environmental Microbiology, 2021, 23, 4017-4033.	3.8	10
6	Multiform antimicrobial resistance from a metabolic mutation. Science Advances, 2021, 7, .	10.3	25
7	Multiple acyl-CoA dehydrogenase deficiency kills Mycobacterium tuberculosis in vitro and during infection. Nature Communications, 2021, 12, 6593.	12.8	11
8	Depletion of the DarG antitoxin in <i>Mycobacterium tuberculosis</i> triggers the DNAâ€damage response and leads to cell death. Molecular Microbiology, 2020, 114, 641-652.	2.5	24
9	The membrane protein ANKH is crucial for bone mechanical performance by mediating cellular export of citrate and ATP. PLoS Genetics, 2020, 16, e1008884.	3.5	45
10	Dissociation of Adaptive Thermogenesis from Glucose Homeostasis in Microbiome-Deficient Mice. Cell Metabolism, 2020, 31, 592-604.e9.	16.2	54
11	Aspartate aminotransferase Rv3722c governs aspartate-dependent nitrogen metabolism in Mycobacterium tuberculosis. Nature Communications, 2020, 11, 1960.	12.8	44
12	Title is missing!. , 2020, 16, e1008884.		0
13	Title is missing!. , 2020, 16, e1008884.		0
14	Title is missing!. , 2020, 16, e1008884.		0
15	Title is missing!. , 2020, 16, e1008884.		0
16	Verapamil Targets Membrane Energetics in Mycobacterium tuberculosis. Antimicrobial Agents and Chemotherapy, 2018, 62, .	3.2	79
17	Fumarase Deficiency Causes Protein and Metabolite Succination and Intoxicates Mycobacterium tuberculosis. Cell Chemical Biology, 2017, 24, 306-315.	5.2	44
18	Metabolic Perspectives on Persistence. Microbiology Spectrum, 2017, 5, .	3.0	14

Robert S Jansen

#	Article	IF	CITATIONS
19	Emerging Approaches to Tuberculosis Drug Development: At Home in the Metabolome. Trends in Pharmacological Sciences, 2017, 38, 393-405.	8.7	22
20	Metabolite profiling of the multiple tyrosine kinase inhibitor lenvatinib: a cross-species comparison. Investigational New Drugs, 2016, 34, 300-318.	2.6	12
21	<scp>MRP</scp> 1 mediates folate transport and antifolate sensitivity in <i>Plasmodium falciparum</i> . FEBS Letters, 2016, 590, 482-492.	2.8	13
22	<i>N</i> -lactoyl-amino acids are ubiquitous metabolites that originate from CNDP2-mediated reverse proteolysis of lactate and amino acids. Proceedings of the National Academy of Sciences of the United States of America, 2015, 112, 6601-6606.	7.1	63
23	ATP-binding Cassette Subfamily C Member 5 (ABCC5) Functions as an Efflux Transporter of Glutamate Conjugates and Analogs. Journal of Biological Chemistry, 2015, 290, 30429-30440.	3.4	47
24	Incorporation of concentration data below the limit of quantification in population pharmacokinetic analyses. Pharmacology Research and Perspectives, 2015, 3, e00131.	2.4	127
25	ABCC6–Mediated ATP Secretion by the Liver Is the Main Source of the Mineralization Inhibitor Inorganic Pyrophosphate in the Systemic Circulation—Brief Report. Arteriosclerosis, Thrombosis, and Vascular Biology, 2014, 34, 1985-1989.	2.4	246
26	ABCC6 prevents ectopic mineralization seen in pseudoxanthoma elasticum by inducing cellular nucleotide release. Proceedings of the National Academy of Sciences of the United States of America, 2013, 110, 20206-20211.	7.1	218
27	Mass Balance Study of [14C]Eribulin in Patients with Advanced Solid Tumors. Drug Metabolism and Disposition, 2012, 40, 313-321.	3.3	27
28	Metabolite Profiling of Bendamustine in Urine of Cancer Patients after Administration of [¹⁴ C]Bendamustine. Drug Metabolism and Disposition, 2012, 40, 1297-1307.	3.3	9
29	Decitabine triphosphate levels in peripheral blood mononuclear cells from patients receiving prolonged low-dose decitabine administration: a pilot study. Cancer Chemotherapy and Pharmacology, 2012, 69, 1457-1466.	2.3	18
30	Gene polymorphisms, pharmacokinetics, and hematological toxicity in advanced non-small-cell lung cancer patients receiving cisplatin/gemcitabine. Cancer Chemotherapy and Pharmacology, 2012, 69, 25-33.	2.3	27
31	Phase I Study of Oral Gemcitabine Prodrug (LY2334737) Alone and in Combination with Erlotinib in Patients with Advanced Solid Tumors. Clinical Cancer Research, 2011, 17, 6071-6082.	7.0	44
32	Deoxyuridine analog nucleotides in deoxycytidine analog treatment: secondary active metabolites?. Fundamental and Clinical Pharmacology, 2011, 25, 172-185.	1.9	12
33	Mass spectrometry in the quantitative analysis of therapeutic intracellular nucleotide analogs. Mass Spectrometry Reviews, 2011, 30, 321-343.	5.4	28
34	Facile Small Scale Synthesis of Nucleoside 5′-Phosphate Mixtures. Nucleosides, Nucleotides and Nucleic Acids, 2010, 29, 14-26.	1.1	6
35	Simultaneous quantification of emtricitabine and tenofovir nucleotides in peripheral blood mononuclear cells using weak anion-exchange liquid chromatography coupled with tandem mass spectrometry. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences 2010 878 621-627	2.3	23
36	Coadministration of Ritonavir Strongly Enhances the Apparent Oral Bioavailability of Docetaxel in Patients with Solid Tumors. Clinical Cancer Research, 2009, 15, 4228-4233.	7.0	66

Robert S Jansen

#	Article	IF	CITATIONS
37	Pharmacokinetics of Gemcitabine and Metabolites in a Patient with Double-Sided Nephrectomy: A Case Report and Review of the Literature. Oncologist, 2009, 14, 944-948.	3.7	9
38	Protein versus DNA as a marker for peripheral blood mononuclear cell counting. Analytical and Bioanalytical Chemistry, 2009, 395, 863-867.	3.7	13
39	Simultaneous quantification of 2′,2′â€difluorodeoxycytidine and 2′,2′â€difluorodeoxyuridine nucleosi and nucleotides in white blood cells using porous graphitic carbon chromatography coupled with tandem mass spectrometry. Rapid Communications in Mass Spectrometry, 2009, 23, 3040-3050.	des 1.5	23
40	Retention studies of 2′-2′-difluorodeoxycytidine and 2′-2′-difluorodeoxyuridine nucleosides and nucleotides on porous graphitic carbon: Development of a liquid chromatography–tandem mass spectrometry method. Journal of Chromatography A, 2009, 1216, 3168-3174.	3.7	45
41	Contribution of the drug transporter ABCG2 (breast cancer resistance protein) to resistance against anticancer nucleosides. Molecular Cancer Therapeutics, 2008, 7, 3092-3102.	4.1	68
42	Oral Administration of Gemcitabine in Patients with Refractory Tumors: A Clinical and Pharmacologic Study. Clinical Cancer Research, 2008, 14, 3477-3486.	7.0	55
43	Development and validation of an assay for the quantitative determination of cladribine nucleotides in MDCKII cells and culture medium using weak anionâ€exchange liquid chromatography coupled with tandem mass spectrometry. Rapid Communications in Mass Spectrometry, 2007, 21, 4049-4059.	1.5	20
44	Quantitative analysis of gemcitabine triphosphate in human peripheral blood mononuclear cells using weak anion-exchange liquid chromatography coupled with tandem mass spectrometry. Journal of Mass Spectrometry, 2006, 41, 1633-1642.	1.6	55
45	Pharmacogenetic Screening of CYP3A and ABCB1 in Relation to Population Pharmacokinetics of Docetaxel. Clinical Cancer Research, 2006, 12, 5786-5793.	7.0	115
46	Multidrug Resistance Protein 2 Is an Important Determinant of Paclitaxel Pharmacokinetics. Clinical Cancer Research, 2006, 12, 6125-6132.	7.0	88
47	LC-MS/MS systematic toxicological analysis: Comparison of MS/MS spectra obtained with different instruments and settings. Clinical Biochemistry, 2005, 38, 362-372.	1.9	86